Tesamorelin: the GHRH peptide with a real FDA approval behind it

Tesamorelin is the one peptide in this whole field that walked into the FDA and walked out with a drug approval. Most of what gets sold in this world runs on animal data and optimism. This one has a Phase 3 trial, a brand name on a pharmacy shelf, and a regulator’s signature. That is rare, and it matters.

What it goes after is the fat you can’t pinch — the deep stuff, packed in behind the abdominal wall and wrapped around your organs. Not the soft layer under the skin. The dangerous kind. And there’s real human evidence tesamorelin brings it down. Start there, because that’s the part worth getting excited about.

What it could actually do for you

Start with the fat, because that’s the headline.

The soft belly fat you can grab is mostly a cosmetic annoyance. Visceral fat is the one that matters — it sits deeper, packed around your liver and gut, and it drives the real trouble: the rising triglycerides, the creeping insulin resistance, the low-grade inflammation you can’t see in the mirror. Tesamorelin’s whole trick is that it goes after that deep fat specifically. It targets the fat that’s actually hurting you.

In the trials it did more than shrink the fat, too. Triglycerides fell. Inflammation markers came down. In one study even the lining of the arteries drifted in the right direction. So the picture isn’t just a flatter waistline — it’s the deep, dangerous fat coming down and the bloodwork that tracks with it improving alongside. For a man watching his waist thicken and his numbers slide in his forties, that’s a genuinely exciting target.

Why the biology is worth a second look

Most growth-hormone products do the obvious, blunt thing: inject growth hormone straight in. Tesamorelin doesn’t. It’s a copy of the natural signal — GHRH — that your own brain uses to tell your pituitary to release its own growth hormone, in the same steady pulses it always has. You’re not overriding the system. You’re nudging it.

The clever part is a small chemical tweak on one end of the molecule that stops your body from breaking it down so fast. Native GHRH is gone in minutes. Tesamorelin hangs around long enough for a once-a-day injection to actually do the job — which is the difference between a lab curiosity and a real drug. And because it leans on your own pituitary instead of flooding you from outside, the growth-hormone release stays closer to the rhythm your body already runs on.

The honest boundary

Here’s where the excitement needs a hard edge, and with tesamorelin the edge is unusually specific.

The approval — the Phase 3 trial, the FDA sign-off, all of it — is for exactly one group of people: HIV patients who develop a particular kind of fat build-up from their medication, a condition called lipodystrophy. That’s who Falutz and colleagues studied in 2007: 412 of them, over 26 weeks. The deep fat fell about 15% on tesamorelin and actually rose 5% on placebo. Real trial, real placebo arm, clear result. That’s the strongest human data in the entire GHRH class, and it deserves respect.

But almost nobody buying tesamorelin for their waistline has HIV lipodystrophy. They’re taking it off-label — for general fat loss and the longevity angle — and that’s a different bet. How much of the off-label case is actually proven? One trial. Makimura and colleagues, 2012: 60 non-HIV adults with sluggish growth-hormone output, followed for a year. It worked — the deep fat came down, the metabolic markers improved, blood sugar held steady. But it’s one small study. Sixty people. Not the mountain of evidence sitting behind the HIV approval.

So the honest read: tesamorelin plainly works for the narrow thing it was approved for, and there’s one good early signal it carries over to the rest of us. That signal is promising. It is not proof. And what years of gently nudged growth hormone does inside an otherwise healthy man chasing longevity — nobody has run that study yet.

Where the regulators sit

Here tesamorelin flips the usual script. Every other peptide in this series is still fighting to become a legal drug. Tesamorelin already is one.

It sells as Egrifta, first approved back in November 2010 under drug application NDA 022505. The product has been through a couple of versions since; the current one, Egrifta WR, was approved in March 2025. Being an approved drug cuts both ways. A licensed doctor can legally prescribe it off-label — that part’s fine. But because tesamorelin is the active ingredient in a drug you can already buy, the rules sharply limit compounding pharmacies from mixing up a cheaper copy of it. That’s the same wall PT-141 runs into, and the exact opposite of BPC-157, which has no approved version to copy in the first place. What a compounding review actually weighs is a longer story, told in what a PCAC review actually is.

It’s also why tesamorelin sits on neither the July 2026 PCAC review list nor the early-2027 one. Those meetings exist to evaluate unapproved bulk substances. Tesamorelin already cleared the higher bar — it’s a finished drug — so it was never in that queue to begin with.

One more thing, for anyone who competes. Tesamorelin is on the WADA prohibited list, in the growth-hormone-factor category, banned both in and out of competition. If you get tested, treat it as off-limits.

What happens next

Step back, and tesamorelin’s real value comes into focus. It has already done the hardest thing in this field — survived a Phase 3 trial and come out the far side as an approved drug, with the deep-fat effect measured, not guessed at. The open question isn’t whether it works. It’s how far that approved result stretches past the single population it was proven in. And that’s the kind of question a trial can answer, once someone runs it.

The version worth waiting for looks nothing like a vial ordered off a research-chemical site and a dose you eyeballed yourself. It looks like a physician who’s actually read your bloodwork, a US-licensed pharmacy, a known quantity in the syringe, and a straight conversation about where the approval ends and the off-label hope begins. Wolverine Health is built to be exactly that — the legitimate version of a thing people are already scoring the risky way. The law has to move first, which is the plain reason the door isn’t open yet. Put your name on the list and we’ll come find you the day it’s legal to do this properly.